Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomized eye

Brian R Kosobucki ¹, William R Freeman ^1* and Lingyun Cheng ¹

¹ University of California, San Diego, United States

^* To whom correspondence should be addressed. E-mail: freeman{at}eyecenter.ucsd.edu.

Accepted 24 January 2006

Abstract

Purpose: We wished to determine the duration of residence of triamcinolone in the vitrectomized eye.

Methods: Twenty-three eyes of 23 patients underwent intravitreal injection of high dose (20 mg) decanted triamcinolone acetonide (Kenalog) at the conclusion of vitrectomy surgery or in previously vitrectomized eyes with macular edema from diabetes, uveitis, cataract surgery, or other surgery.

Results: The median time to disappearance of triamcinolone in the vitrectomized eye was 113 days (95% confidence interval (CI) 85-191 days). In the phakic eyes the median time to disappearance was 191 days (95% CI 148-191 days). In the pseudophakic eyes the median time to disappearance was 102 days (95% CI 85-113 days). This difference was not significant (p=0.12). There were no cases of endophthalmitis or severe inflammatory reaction. Five eyes (22%) experienced IOP rise >10 mm Hg.

Conclusions: High dose decanted intravitreal triamcinolone has a median residence time of 113 days in the vitrectomized eye. Although this appears to be shorter than in the non-vitrectomized eye, this study suggests that a sufficient duration of action will be present to be clinically useful.

Keywords: diabetes, macular degeneration, macular edema, triamcilone, vitreous injection

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

BJO at a glance

Creig Hoyt
Br. J. Ophthalmol. 2006 90: 663. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Tammewar, A M, Cheng, L, Kayikcioglu, O R, Falkenstein, I A, Kozak, I, Goldbaum, M H, Freeman, W R (2008). Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections. Br. J. Ophthalmol. 92: 810-813 [Abstract] [Full Text]